ArticleTrends in cancer2016
The evolution of lifespan and age-dependent cancer risk.
Article in Trends in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- All-cause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Biological aging and generational shifts in early-onset cancer risk.Nature medicine · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Hematopoietic (stem) cells-The elixir of life?FEBS letters · 2026Review
- Intranasal administration of temozolomide conjugated nanoparticles with transcranial magnetic stimulation improves the survival in glioblastoma xenograft models.Drug delivery and translational research · 2026Article
- Clinical Characteristics of Late-Onset (≥ 65 Years) Ulcerative Colitis: A Single-Center Retrospective Study.Gastroenterology research and practice · 2026Article
- Telomerase-active urine-derived stem cells: Regenerative solutions for aging.Ageing research reviews · 2026Review
- Evolutionary Dynamics of Oncosuppression Under Selection Pressure.Life (Basel, Switzerland) · 2025Article
- Prognostic Potential of Cancer-Associated Fibroblast Surface Markers and Their Specific DNA Methylation in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Mammalian Species-Specific Resistance to Mammary Cancer.Journal of mammary gland biology and neoplasia · 2025Review
- Altered Atlas of Exercise-Responsive MicroRNAs Revealing miR-29a-3p Attacks Armored and Cold Tumors and Boosts Anti-B7-H3 Therapy.Research (Washington, D.C.) · 2025Article
- Article
- Cancer: A Disease of Modern Times?Cureus · 2024Review
- Septic shock in the immunocompromised cancer patient: a narrative review.Critical care (London, England) · 2024Review
- Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- Progressive senescence programs induce intrinsic vulnerability to aging-related female breast cancer.Nature communications · 2024Article
- Arginines of the CGN codon family are Achilles' heels of cancer genes.Scientific reports · 2024Article
- Efficacy and safety of tacrolimus in older adults with ulcerative colitis: a retrospective study.BMC gastroenterology · 2024Article
- A Poisson distribution-based general model of cancer rates and a cancer risk-dependent theory of aging.Aging · 2023Article
- The Frailty Index and colon cancer: a 2-sample Mendelian-randomization study.Journal of gastrointestinal oncology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The Armitage-Doll multi-stage model of carcinogenesis tremendously refocused cancer science by postulating that carcinogenesis is driven by a sequence of genetic changes in cells. Age-dependent cancer incidence thus has been explained in terms of the time necessary for oncogenic mutations to occur. While the multi-step nature of cancer evolution is well-supported by evidence, the mutation-centric theory is unable to explain a number of phenomena, such as the disproportion between cancer frequency and animal body size or the scaling of cancer incidence to animal lifespan. In this paper, we present a theoretical review of the current paradigm and discuss some fundamental evolutionary theory postulates that explain why cancer incidence is a function of lifespan and physiological, not chronological, aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.